The EU Biotech Act: Proposed Reforms to Enhance Clinical Trials in Europe

On Tuesday, December 16, the European Commission presented its proposal for the Biotech Act - a regulation aimed at making Europe more attractive and competitive in the field of biotechnology. The proposal includes a simplified regulatory framework for clinical trials by amending Regulation (EU) No 536/2014. The proposed objectives and measures include:

Strengthening the Coordination of Multinational Clinical Trials

• Empowering the Reporting Member State (RMS) to lead the scientific, ethical, and regulatory evaluation of clinical trials.
• Conducting an integrated ethical review by the RMS for Part I of the assessment.
• Enhancing trust and mutual recognition between Member States.

Increasing Flexibility

• Allowing parallel applications for substantial modifications.
• Facilitating more efficient and predictable interactions between sponsors and authorities during the evaluation process.
• Enabling direct-to-patient delivery and distribution of investigational medicinal products (IMPs).

Harmonization and Simplification

• Introducing a single dossier for documentation related to investigational medicinal products.
• Mandating the use of EU-harmonised templates.
• Establishing a unified assessment process for combination studies involving medicinal products and medical devices/IVDs.
• Creating a harmonised legal basis for the processing of personal data.
• Introducing a new study category, "minimal intervention," with risk-adapted requirements.

Facilitating Innovation

• Supporting the use of AI and digital tools in clinical trials.
• Implementing regulatory sandboxes for safe testing of innovative approaches.
• Providing exemptions from environmental risk assessments for GMO-based investigational ATMPs.
• Accelerating processes to address public health crises.

To learn more about the proposal, including all related documents and press materials, visit the European Commission's website.